Factors influencing the acceleration of human factor XIa inactivation by antithrombin III.
Controversy exists in the literature concerning the potentiating effect of heparin on the inactivation rate of factor XIa by antithrombin III (AT III) in both purified systems and in plasma. We have analyzed the factors that could influence this reaction and found that ionic strength of the medium, as well as the type and concentration of the heparin preparations accounted for the major discrepancies in the literature. At I = 0.43 N, a preparation of bovine lung heparin at 1 U/mL did not augment the inactivation rate of factor XIa by inhibitors in plasma or by purified AT III. However, when ionic strength was decreased, a progressive increase in the potentiating effect was observed, reaching 6.5-fold at I = 0.15 N. At saturating concentrations of heparin, which results in the formation of 100% AT III-heparin complex, (greater than ten-fold molar excess over AT III) in purified systems, all heparin preparations (porcine, bovine, low molecular weight [LMW], and high affinity) yielded an approximately 30-fold augmentation of the factor XIa inactivation rate. However, when heparin was less than saturating, we observed that various heparin preparations affected the AT III-induced inactivation of factor XIa to different degrees even though they exhibited the same inhibitory activity (1 U/mL) against thrombin. This variation resulted from differences in the number of AT III binding sites in each heparin preparation, despite a similar Kd for each. Addition of high molecular weight kininogen (HK) to AT III-heparin complexes did not enhance their ability to inhibit factor XIa, and high concentrations of HK decreased the inactivation rate. A high therapeutic dose of heparin only permits the formation of 2.5% to 16.5% of the AT III-heparin complexes that can be achieved at saturation. We observed that 1 U/mL heparin (bovine lung heparin) (high therapeutic concentration) in virtually undiluted plasma only accelerated the inactivation rate of factor XIa (in the absence of other active enzymes) less than two-fold. These new observations further support our previous conclusion that therapeutic levels of heparin have little to no influence on the inactivation rate of factor XIa in plasma.
Scott
C F
CF
Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140.
Colman
R W
RW
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D002417:Cattle; D005172:Factor XI / Q000378:metabolism*; D015945:Factor XIa; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007413:Intestinal Mucosa; D007700:Kinetics; D008168:Lung; D008970:Molecular Weight; D009994:Osmolar Concentration; D013045:Species Specificity; D013552:Swine
D000990:Antithrombin III; D006493:Heparin; D005172:Factor XI; D015945:Factor XIa